NCT00002252已完成不适用
A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Sandoz
- 试验地点
- 45
研究概览
简要总结
To determine the efficacy and safety of Sandostatin (octreotide) compared to placebo in controlling diarrhea which is a manifestation or complication of documented HIV infection and which is refractory (does not respond) to all known treatment classes.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have the following:
- •Uncontrolled diarrhea that is either a manifestation or complication of documented HIV infection.
- •Ability to communicate, participate, and comply with the requirements of the study.
- •Capability of self administering injections of study medication or have responsible family member or companion who can.
- •Given written consent prior to study entry.
- •Prior Medication:
- •At least two weeks of conventional dosing regimens of antidiarrheal medication (e.g.:
- •Lomotil, Imodium, Paregoric) within one month prior to study entry. OR Patients with evidence of upper or lower GI infection(s) for which there is approved, potentially curative therapy must have failed appropriate treatment for at least two weeks.
排除标准
- •Co-existing Condition:
- •Patients with the following conditions or symptoms are excluded:
- •Evidence of underlying immunosuppressive disease other than due to HIV.
- •Diarrhea caused by a known gastrointestinal disorder such as idiopathic ulcerative colitis, Crohn's disease, acute stool culture positive bacterial colitis (documented within the last 2 weeks prior to study entry AND not having at least 2 weeks of antibiotic therapy), pseudomembranous colitis (Clostridium difficile toxin positive), short gut syndrome, chronic pancreatitis (alcoholic or idiopathic), ischemic bowel disease, or enteroenteric fistulae.
- •Patients with the following are excluded:
- •Diarrhea that can be controlled with conventional antidiarrheal agents.
- •Stool weight at either of the 2 baseline periods that average < 500 g/day.
- •Evidence of underlying immunosuppressive disease other than due to HIV.
- •Diarrhea caused by other gastrointestinal disorders not related to HIV.
- •Prior Medication:
- •Previously treated with Sandostatin as an anti-diarrheal agent.
- •Experimental antidiarrheal drugs within one month of study entry.
- •Present intravenous drug abuse.
研究者
研究点 (45)
Loading locations...
相似试验
已完成
2 期
Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer PatientsProstate CancerNCT00166725Novartis40
已完成
3 期
A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet SyndromeDravet Syndrome (DS)NCT04940624Takeda144
已完成
不适用
Randomized, placebo controlled, patient and observer masked study to evaluate the efficacy of treatment with Sandostatin LAR 20 mg i.m. or placebo every 4 weeks during 6 months in 120 patients with exudative age-related macular degeneration.NL-OMON25954120
已完成
3 期
A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut SyndromeLennox Gastaut Syndrome (LGS)NCT04938427Takeda270
进行中（未招募）
2 期
Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged AntibioticsPancreatic DiseasesNCT04329039Mayo Clinic103